
Product Data Sheet

Product Name: Cefpodoxime (free acid)

Cat. No.: GC10817

Chemical Properties

Cas. No. 80210-62-4

Chemical Name (6R)-7R-[[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

SMILES O=C(N1[C@]2([H])SCC(COC)=C1C(O)=O)[C@H]2NC(/C(C3=CSC(N)=N3)=N\OC)=O

Formula $C_{15}H_{17}N_5O_6S_2$

M.Wt 427.5

Solubility ≤ 10 mg/ml in ethanol; 10mg/ml in DMSO; 10mg/ml in methanol; 5mg/ml in acetonitrile

Store
Storage at -
20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure **Background**

Cefpodoxime, as known as R 3763, is a metabolite of cefpodoxime proxetil. It is demonstrated that cefpodoxime, as an oral third generation cephalosporin antibiotic, is active against most Gram-positive and Gram-negative bacteria.

Cefpodoxime suppresses bacterial septum and cell wall synthesis by binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane.

In vitro: Cefpodoxime showed antibacterial activities against obligatory anaerobes and salmonella spp., shigella spp. and Neisseria meningitides. The activity of cefpodoxime was less active than R95867, an active form of CS-834, against Gram-negative bacteria [1]. Cefpodoxime was quite stable to hydrolysis by β -lactamases produced from B. cereus and E. coli HB101/pBR322 [2].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In vivo: Male ddY mice were administered orally in a volume of 0.2 mL of 0.5% carboxymethyl cellulose sodium salt. After 7 days, it was shown that cefpodoxime had good efficacy against streptococcus spp. and K. pneumoniae infection in mice [1].

References:

- [1]. Sakagawa, E., Otsuki, M., Oh, T., & Nishino, T. In-vitro and in-vivo antibacterial activities of CS-834, a new oral carbapenem. *Journal of Antimicrobial Chemotherapy*, 1998; 42: 426-437.
- [2]. Fukuoka, T., Ohya, S., Utsui, Y., Domon, H., Takenouchi, T., Koga, T., ... Kuwahara, S. In vitro and in vivo antibacterial activities of CS-834, a novel oral carbapenem. *Antimicrobial Agents and Chemotherapy*, 1997; 41(12): 2652-2663.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA